Literature DB >> 25217680

Trends in high-dose opioid prescribing in Canada.

Tara Gomes1, Muhammad M Mamdani2, J Michael Paterson3, Irfan A Dhalla4, David N Juurlink5.   

Abstract

OBJECTIVE: To describe trends in rates of prescribing of high-dose opioid formulations and variations in opioid product selection across Canada.
DESIGN: Population-based, cross-sectional study.
SETTING: Canada. PARTICIPANTS: Retail pharmacies dispensing opioids between January 1, 2006, and December 31, 2011. MAIN OUTCOME MEASURES: Opioid dispensing rates, reported as the number of units dispensed per 1000 population, stratified by province and opioid type.
RESULTS: The rate of dispensing high-dose opioid formulations increased 23.0%, from 781 units per 1000 population in 2006 to 961 units per 1000 population in 2011. Although these rates remained relatively stable in Alberta (6.3% increase) and British Columbia (8.4% increase), rates in Newfoundland and Labrador (84.7% increase) and Saskatchewan (54.0% increase) rose substantially. Ontario exhibited the highest annual rate of high-dose oxycodone and fentanyl dispensing (756 tablets and 112 patches per 1000 population, respectively), while Alberta's rate of high-dose morphine dispensing was the highest in Canada (347 units per 1000 population). Two of the highest rates of high-dose hydromorphone dispensing were found in Saskatchewan and Nova Scotia (258 and 369 units per 1000 population, respectively). Conversely, Quebec had the lowest rate of high-dose oxycodone and morphine dispensing (98 and 53 units per 1000 population, respectively).
CONCLUSION: We found marked interprovincial variation in the dispensing of high-dose opioid formulations in Canada, emphasizing the need to understand the reasons for these differences, and to consider developing a national strategy to address opioid prescribing. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25217680      PMCID: PMC4162700     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  23 in total

1.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

2.  Chronic pain at ages 12 to 44.

Authors:  Pamela L Ramage-Morin; Heather Gilmour
Journal:  Health Rep       Date:  2010-12       Impact factor: 4.796

3.  Opioid analgesics and rates of fatal drug poisoning in the United States.

Authors:  Leonard J Paulozzi; George W Ryan
Journal:  Am J Prev Med       Date:  2006-12       Impact factor: 5.043

4.  Opioid prescriptions for chronic pain and overdose: a cohort study.

Authors:  Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

5.  The impact of sampling and measurement on the prevalence of self-reported pain in Canada.

Authors:  Elizabeth G Van Den Kerkhof; Wilma M Hopman; Tanveer E Towheed; Tassos P Anastassiades; David H Goldstein
Journal:  Pain Res Manag       Date:  2003       Impact factor: 3.037

6.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 7.  Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline.

Authors:  Roger Chou; Jane C Ballantyne; Gilbert J Fanciullo; Perry G Fine; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

8.  Trends in long-term opioid therapy for chronic non-cancer pain.

Authors:  Denise Boudreau; Michael Von Korff; Carolyn M Rutter; Kathleen Saunders; G Thomas Ray; Mark D Sullivan; Cynthia I Campbell; Joseph O Merrill; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-12       Impact factor: 2.890

9.  Medicaid prior authorization and controlled-release oxycodone.

Authors:  Nancy E Morden; Judy T Zerzan; Tessa C Rue; Patrick J Heagerty; Elizabeth E Roughead; Stephen B Soumerai; Dennis Ross-Degnan; Sean D Sullivan
Journal:  Med Care       Date:  2008-06       Impact factor: 2.983

10.  Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US-Canada border.

Authors:  Tara Gomes; J Michael Paterson; David N Juurlink; Irfan A Dhalla; Muhammad M Mamdani
Journal:  Open Med       Date:  2012-11-13
View more
  54 in total

1.  Illicit fentanyls in the opioid street market: desired or imposed?

Authors:  Sarah G Mars; Daniel Rosenblum; Daniel Ciccarone
Journal:  Addiction       Date:  2018-12-04       Impact factor: 6.526

Review 2.  Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews.

Authors:  Charl Els; Tanya D Jackson; Diane Kunyk; Vernon G Lappi; Barend Sonnenberg; Reidar Hagtvedt; Sangita Sharma; Fariba Kolahdooz; Sebastian Straube
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

3.  Post-war prevention: Emerging frameworks to prevent drug use after the War on Drugs.

Authors:  Dan Werb
Journal:  Int J Drug Policy       Date:  2017-07-19

4.  Surgeons as advocates for opioid control

Authors:  Chad G. Ball
Journal:  Can J Surg       Date:  2019-08-01       Impact factor: 2.089

5.  High-strength opioid formulations: the case for a ministerial recall.

Authors:  Matthew Herder; David Juurlink
Journal:  CMAJ       Date:  2018-12-03       Impact factor: 8.262

6.  Effective Canadian policy to reduce harms from prescription opioids: learning from past failures.

Authors:  Benedikt Fischer; Jürgen Rehm; Mark Tyndall
Journal:  CMAJ       Date:  2016-11-07       Impact factor: 8.262

7.  National opioid crisis.

Authors:  Abhimanyu Sud
Journal:  CMAJ       Date:  2016-10-18       Impact factor: 8.262

Review 8.  The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight.

Authors:  Joseph K Eibl; Kristen Morin; Esa Leinonen; David C Marsh
Journal:  Can J Psychiatry       Date:  2017-05-19       Impact factor: 4.356

9.  At-a-glance - What can social media tell us about the opioid crisis in Canada?

Authors:  Semra Tibebu; Vicky C Chang; Charles-Antoine Drouin; Wendy Thompson; Minh T Do
Journal:  Health Promot Chronic Dis Prev Can       Date:  2018-06       Impact factor: 3.240

10.  American Society for Enhanced Recovery and Perioperative Quality Initiative-4 Joint Consensus Statement on Persistent Postoperative Opioid Use: Definition, Incidence, Risk Factors, and Health Care System Initiatives.

Authors:  Michael L Kent; Robert W Hurley; Gary M Oderda; Debra B Gordon; Eric Sun; Monty Mythen; Timothy E Miller; Andrew D Shaw; Tong J Gan; Julie K M Thacker; Matthew D McEvoy
Journal:  Anesth Analg       Date:  2019-08       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.